Our data confirmed that common RET variants, identified during routine genetics diagnostics and classified clinically as benign, did not differ between MTC patients and healthy controls at a level that would be discriminative for the risk of MTC development. This evidence concerns the gene RET and medullary thyroid gland carcinoma.